Can Huang

PD-L1+ exosomes as biomarkers and therapeutic targets in multiple myeloma: implications for CAR-T efficacy and combination immunotherapy

Although chimeric antigen receptor T-cell (CAR-T) therapy has reshaped the treatment landscape for relapsed/refractory multiple myeloma (RRMM), durable remission remains challenging. T-cell dysfunction and exhaustion are key obstacles to long-term efficacy. Programmed death-ligan...